M2 PHARMA-December 26, 2018-European Medicines Agency Grants Orphan Drug Designation for Xeris' Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)
(NASDAQ: XERS) has received Orphan Medicinal Product designation from the European Medicines Agency for its investigational ready-to-use liquid glucagon as a treatment for non-insulinoma pancreatogenous hypoglycaemia syndrome (NIPHS), a spectrum of metabolic conditions, which includes post-bariatric hypoglycemia, the company said.
We speculate that compounds related to 9-phenanthrol could potentially be useful, for instance, in the development of drugs for the treatment of patients with pancreatogenous
hyperinsulinemic hypoglycemia syndromes .
Mediwala et al., "Reversible Adrenal insufficiency in three patients with Post-Roux-en-Y gastric bypass nomnsulmoma pancreatogenous
hypoglycemia syndrome," Journal of Investigative Medicine High Impact Case Reports, pp.
The differential diagnoses of hyperinsulinemic hypoglycemia include familial persistent hyperinsulinemic hypoglycemia, primary islet-cell hyperplasia, noninsulinoma pancreatogenous
hypoglycemic syndrome, insulinoma, and factitious hypoglycemia (6).
In adults, apart from an insulinoma, HH has been reported with several conditions, including insulin autoimmune syndrome and noninsulinoma pancreatogenous
hypoglycaemia syndrome, and in patients with mutations on the insulin receptor [110, 111].